(Q59571527)

English

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

scientific article published on 22 October 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

phase II clinical trial

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Dror Michaelson

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

7

object named as

Jacek Jassem

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

16

object named as

Corina Dutcus

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

author name string

Thomas E Hutson

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Hilary Glen

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Ana Molina

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Timothy Eisen

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jakub Zolnierek

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jose Pablo Maroto

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Begoña Mellado

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Bohuslav Melichar

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jiri Tomasek

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Alton Kremer

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Han-Joo Kim

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Karen Wood

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

James Larkin

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

22 October 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1473-1482

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

EAU guidelines on renal cell carcinoma: 2014 update.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900290-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00290-9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26482279%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q59571527&oldid=2119126597"